StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for PLRX yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-18 | $1.17 | $1.18 | +0.85% | 1.2M |
| 05-19 | $1.19 | $1.15 | -3.36% | 0.4M |
| 05-20 | $1.16 | $1.20 | +3.45% | 1.6M |
| 05-21 | $1.21 | $1.23 | +1.65% | 0.3M |
| 05-22 | $1.24 | $1.21 | -2.42% | 0.2M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Q3 2024 2024-09-30 | Q2 2024 2024-06-30 |
|---|---|---|---|---|
Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
Operating Income | $-156.37M | $-228.37M | $-175.04M | $-113.03M |
Net Income | $-149.34M | $-210.30M | $-160.57M | $-55.85M |
EPS (Diluted) | $-2.43 | $-3.47 | $-2.66 | $-1.71 |
Total Assets | $225.23M | $396.95M | $445.67M | $483.73M |
Total Liabilities | $44.02M | $92.87M | $99.84M | $91.05M |
Cash & Equivalents | $45.45M | $71.19M | $79.62M | $80.39M |
Free Cash Flow OCF − CapEx | $-128.71M | $-159.35M | $-111.48M | $-78.31M |
Shares Outstanding | 61.45M | 60.86M | 60.85M | 60.43M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.